In this beautiful season of "wet with apricot blossom rain, not cold with willow wind", the work conference of 2024 Kelun-Biotech was grandly held in Chengdu from April 10th to 12th. Mr. Liu Gexin, Chairman of the Board, Mr. Liu Sichuan, General Manager of the Group, senior management team, relevant persons in charge of each subsidiary (branch) company, each marketing area and all departments directly under the company attended the meeting, and at the same time, the whole meeting was broadcasted in the form of video, with a total number of more than 4,000 people attending the meeting. According to the agenda of the meeting, the 11th was synchronized with the meeting of the industrial sub-groups and marketing sub-groups, and the morning of the 12th was the working conference of the group. A total of 39 speakers made presentations and focused on the short-term and future trends of production and marketing.
The year of 2023 is the year when Kelun resolutely implements the "Twenty Character Guidelines" and continues to move forward victoriously, and the vision and courage of all the fighters extend the road of success of Kelun here. The successful spin-off and listing of Chuanning Biologicals and Kelun-Biotech, Kelun has formed a "character" structure operation platform, and as of March 2024, the total market capitalization has exceeded 100 billion yuan, becoming a pioneering force to lead the industry's high-quality development.
The industrial sub-group meeting focused on safety, quality, cost and other core themes. Kelun Drug Research Institute, Xindu Base, Hunan Kelun, Yueyang Branch, Hubei Kelun, Qionglai Branch focused on research and production linkage, production and marketing linkage, intelligent manufacturing, and high-quality development were comprehensively summarized.
The EHS Supervision Department, a department directly under the headquarters, focused on problems, prevented small steps, strengthened the construction of the safety system and the implementation of responsibilities, and continued to optimize the safety system and strengthen the safety culture with the help of PMS and other management tools. The Cost Management Committee put forward the company's thoughts and requirements on cost management from optimizing cost management, efficient linkage cost reduction, etc., and formulated a cost-saving incentive program, which injected a powerful agent for the production enterprises to continuously reduce costs and increase efficiency. The General Manager's Department made an in-depth summary around the dimensions of solidifying the quality cornerstone, creating an economic supply center, innovation empowerment, and improving quality and efficiency, and made important work plans and deployments in promoting industrial upgrading, and creating a competitive advantage in quality and cost.
The agenda of the meeting was also interspersed with thematic discussion sessions, for the current hotspots and production quality management practices, Internet + safety production, material key attribute assessment and control, supplier control strategy, artificial intelligence and other in-depth discussions, clarifying the management ideas, clearing the direction of the promotion and strategy.
At the end of the theme report, Mr. Liu Gexin, the chairman of the board of directors, commented on the speeches of each theme and pointed out that: soldiers are precious and quick! In the current market environment, through the adjustment of industrial structure, rapid release of production capacity, stabilize market expectations; follow the "Hein's Law", cast product quality shield.
Since its establishment in 2021, under the guidance of the company's "twenty-word policy", Kelun Marketing Center has further improved the company's operational efficiency with reform thinking and innovative approaches. At present, the marketing center is at the intersection of two three-year plans, this meeting comprehensively summarized the first three-year plan and comprehensively deployed the tasks of the second three-year plan.
Core Business Marketing Division, New Drug Marketing Division, Kelun-Biotech Marketing Center, CDMO Business Development Department, Comprehensive Products Division and Large Retail Division analyzed and summarized the sales and market situation of the company's core infusion products and generic innovative products from 2021 to 2023, and put forward the sales planning for 2024 and the long term; Health Strategy Development Research Department, County Business Department, Merchants Department and excellent areas shared the system construction, academic promotion and other multi-dimensional work experience. The Market Access Department, the Integrated Medical Market Department and the Business Department made special reports on the layout of access work, the professional capacity and system construction of academic promotion, and the management of product channels.
After listening carefully to the special report of each spokesman of the marketing sub-group, General Manager of the Marketing Center Fan Wendi made an in-depth and detailed comment, and deployed the second three-year plan of the Marketing Center - Deepening Reform, Steady Transformation, from the four dimensions of organizational optimization and talent cultivation, deepening of the business and comprehensive integration, improving the effectiveness and compliance transformation, and opportunities and problems. He also pointed out that China's pharmaceutical industry has gone through the dilemma of "no drugs available", the market-oriented operation of pulling up seedlings to help them grow, the difficult period of domestic substitution of generic drugs, and the agitation under the innovation dividend, and is now moving towards rationality and maturity. Every day, we must find the long-term trend in the changes and explore new breakthroughs in the unchanged!
Chairman Liu Gexin instructed: the top management has reached a high degree of consensus on the upgrading and transformation of marketing; the ice has been broken, the course has been indicated, and the road has been opened, and we are going to take resolute actions to quickly reach the expected reform goals.
Mr. Deng Xuheng, General Manager of Chuanning Bio, said: Chuanning adheres to the innovative development concept of building industrial alliance in known fields and forming knowledge alliance in unknown fields, and has been at the forefront of the industry in terms of industrial scale, product quality, environmental protection and governance level, and has become the head producer with international discourse power in bulk pharmaceutical raw materials. After listing, Chuanning has focused its resources on the synthetic biology track and completed the research and development of its first synthetic biology product, red myrcene glycol, to commercial production in two years, which fully demonstrated Chuanning's high-quality research and development level and strong industrialization capability. In the future, Chuanning will continue to adhere to the dual-wheel drive strategy of "bio-fermentation" and "synthetic biology", empowering the antibiotic industry and synthetic biology R&D with AI to further consolidate the head position of the traditional antibiotic industry, and at the same time accelerating the research and development and landing of new products, which will contribute to the profitability of Coren Group. At the same time, we will accelerate the research and development of new products, and contribute to the sustainable growth of the profit of Kelun.
On behalf of Kelun Research Institute and Kelun-Biotech, Mr. Ge Junyou, General Manager of Kelun-Biotech, reported the progress of Kelun's drug R&D work in 2023 and the work objectives in 2024, taking into account the current domestic and international regulations and competitive situation. He said: At present, the challenges and opportunities of new drug R&D coexist, Kelun will continue to adhere to the R&D strategy of "Generic drives innovation, innovation drives the future", under the strong and wise leadership of the Chairman, General Manager and the Group, continue to strengthen the full-cycle empowerment of innovative drug R&D by AI technology, focus on key indications and core technology platforms, fully promote international cooperation, and accelerate the development of multiple innovative drugs, as well as the development of new drugs in the future. We will also make every effort to promote international cooperation, accelerate the approval and commercialization of many innovative drugs, maximize the global value of our pipeline, and contribute China's power to the cause of human health!
The awarding ceremony of "The Fifth Group Meeting of Kelun Group" was also held during the meeting, and the top ten outstanding marketing areas in terms of net income and per capita profit for the year of 2023, and the outstanding production enterprises in the "Billion Dollar Club" were awarded respectively. The loyal and brave generals of Kelun marketing business face the challenges with the mindset of accommodating all rivers and the confidence of never giving up; the team will be cohesive as one and the spirit of struggle to achieve the mission frequently show their swords, which is so awe-inspiring and courageous! "It seems to be the most rugged, into as easy but hard", Colum this growing, growing production and technology team, is the foundation and hope for the continued success of the Colum business; it is a group of people who must be cherished and cared for, no matter how it is evaluated will not be too high. We are bold and confident in realizing this year's goal! Let us work together to open a new era of carrying the glory of Kelun, move forward!
Chairman Liu Gexin attended the whole meeting, and after listening to the speeches on industry, marketing, Chuanning Biological and R&D innovation, he put forward opinions and suggestions in light of the actual work and responded to the concerns of all parties.
Chairman Liu Gexin talked about: a bird dares to sing in the fragile branch, why it does not worry about the branch will break? Because it has wings to fly, the enterprise is the same, from the moment of the birth of Kelun, the eagle is our spiritual totem, through the clouds and fog, the eyes of heaven and earth, "Kunpeng wings, ninety thousand miles, turn the shaking goat's horns", which is the ambition of Kelun.
After twenty-eight years of hard work, Coren is at a "high time" that has never been seen before in its history. We must be virtuous and prudent, cautious and fearful; we must adhere to long-termism and value investment, and become a trustworthy company by rewarding investors and society with more excellent results.
In the face of the great changes that have not been seen in a century, embracing change from the bottom of our hearts is the only way to see the opportunities in economic adjustments and business changes. The only way to cope with change is to innovate, which is the essence of entrepreneurship. Success lies not only in talent and luck, but also in the anticipation and selection of quality "tracks", which requires entrepreneurs to have higher wisdom and commitment to explain the present and foresee the future with new knowledge systems and deeper insights. Entrepreneurs' belief in technology, their pursuit of innovation and their confidence in the future are intertwined, and these are great enablers for creating a new era of business.
Whenever we start a new impact, we will seek the regeneration power of "Phoenix Nirvana" from the original civilization of Colum's entrepreneurship, and the spirit of Colum, which is mutually promoting and stimulating, has been honed through the vicissitudes of life and has been deposited in the hearts of Colum's comrades, and will explode when there is a fire.
Today, we are standing on a new starting point, has a completely different state of mind. Warm winds of May will soon blow across the land of China, this is the season belonging to us, since we have chosen a faraway place, we will travel through thick and thin, let's sing for the month of May, and pay homage to those who struggle!
【2024 CSCO：Oral report by Pro.Jing Wang】
【2024 CSCO：Oral report by Dr.Zhuo Yang】
